Drug Combination Details
| General Information of the Combination (ID: C98290) | |||||
|---|---|---|---|---|---|
| Name | Neferine NP Info | + | Cisplatin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Healthy individual
[ICD-11: N.A.]
|
Investigative | [1] | ||
|
Lung cancer
[ICD-11: 2C25]
|
Investigative | [2] | |||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [2] | |||||
| Biological
Regulation |
Down-regulation | ROS generation | ||||
| In-vitro Model | A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Neferine augments therapeutic efficacy of cisplatin through ROS- mediated non-canonical autophagy in human lung adenocarcinoma (A549 cells). | |||||
| Experiment 2 Reporting the Effect of This Combination | [1] | |||||
| Experimental
Result(s) |
Neferine reduces cisplatin-induced nephrotoxicity by enhancing autophagy via the AMPK/mTOR signaling pathway. | |||||
